Granted Patent B2

US 11,839,689 · App. 17/985,235 · Granted Dec 12, 2023

Inventors: Douglas Alan Lorenz (Bend, OR); Sanjay Konagurthu (Bend, OR); Randy J. Wald (Bend, OR); Jason A. Everett (Bend, OR); Sheila Matz (North Conway, NH); Yuuki Takaishi (Tokyo, JP); Toshiro Sakai (Tokyo, JP); Ryousuke Irie (Tokyo, JP); Shinsuke Oba (Tokyo, JP); Hiroyasu Toyota (Tokyo, JP); Koji Nishimura (Tokyo, JP); Atsushi Kanbayashi (Tokyo, JP)

Assignees: Astellas Pharma Inc.; Medivation Prostate Therapeutics LLC

A61K9/2054A61K9/10A61K9/16A61K9/1652A61K9/2095A61K31/4164A61K31/4166A61K47/32A61K47/38C07D233/86

Abstract

Claims (9)

1. A pharmaceutical composition comprising a solid dispersion consisting essentially of amorphous enzalutamide and hydroxypropyl methylcellulose acetate succinate.

2. The pharmaceutical composition according to claim 1 , wherein the solid dispersion is a spray-dried dispersion.

3. A pharmaceutical composition comprising a solid dispersion consisting essentially of amorphous enzalutamide and hydroxypropyl methylcellulose acetate succinate, wherein the solid dispersion is a spray-dried dispersion, and wherein the amorphous enzalutamide remains amorphous following storage of the spray-dried dispersion at 40° C. and 75% relative humidity for 1 month.

4. A tablet comprising the pharmaceutical composition according to claim 2 .

5. The tablet according to claim 4 , wherein the amount of amorphous enzalutamide is 80 mg.

6. The tablet according to claim 4 further comprising croscarmellose sodium and magnesium stearate.

7. A tablet comprising a pharmaceutical composition comprising:

a solid dispersion consisting essentially of amorphous enzalutamide and hydroxypropyl methylcellulose acetate succinate, wherein the solid dispersion is a spray-dried dispersion,; and

croscarmellose sodium and magnesium stearate, wherein the croscarmellose sodium is 6% to 10% of the total tablet weight.

Assignments (13)

Cited By (1)

US 12,611,377